A study in mice demonstrated that the mir-30d is significantly downregulated during all stages of myocardial infarction and exerts anti-apoptotic effects in cardiomyocytes by directly targeting the pro-apoptotic genes Picalm and Skil [Kim et al. DOI:10.1038/s41598-018-33020-x]. In human serum, the mir-30d was found to be downregulated in patients with mild traumatic brain injury at baseline compared to controls, though it was subsequently excluded from further analysis as not suitable for that specific biomarker panel [Polito et al. DOI:10.1007/s11033-020-05386-7].